(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

(R)-5-CARBAMOILPIRIDINA-3-IL-2-METIL-4-(3-(TRIFLUOROMETOXI)BENZIL)PIPERAZINA-1-CARBOXILATO CRISTALINO, COMPOSIÇÕES E MÉTODOS DE USO RESPECTIVOS

Em AnáliseInvention PatentPCT · US2019050771

Application data

Number

112021004340

Type

Invention Patent

Filing

09/12/2019

Publication

05/25/2021

PCT

US2019050771

Progress at the INPI

Technical opinion to answer
  1. Filing09/12/19
  2. Publication05/25/21
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 08/27/2024. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

ABIDE THERAPEUTICS, INC.

US

C. C. (pessoa física)

US

LUNDBECK LA JOLLA RESEARCH CENTER, INC.

US

See this company's full portfolio

Inventors

J. X. (pessoa física)

CN

L. H. (pessoa física)

US

N. T. (pessoa física)

US

N. W. (pessoa física)

US

Q. Z. (pessoa física)

CN

Technical data

Priority claims

US

62/731,014 · 09/13/2018

Abstract

São fornecidas neste documento formas cristalinas de (R)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)benzil)piperazina-1-carboxilato. Também são divulgadas composições farmacêuticas compreendendo formas cristalinas de (R)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)benzil)piperazina-1-carboxilato.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Transferência deferida

#25.1

08/27/2024

RPI 2799

Parecer de pré-exame

#6.23

06/13/2023

RPI 2736

Notificação de entrada na fase nacional - PCT

#1.3

05/25/2021

RPI 2629

Alteração de dados cadastrais

#1.1

03/16/2021

RPI 2619

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.